Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
BASKING RIDGE, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results the second quarter ended June 30, 2024, on Monday, August 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
新泽西州巴斯金里奇，2024年8月5日（环球新闻专线）——开发治疗晚期实体瘤和其他严重疾病创新疗法的临床阶段制药公司Lisata Therapeutics, Inc.（纳斯达克股票代码：LSTA）（“Lisata” 或 “公司”）今天宣布，该公司将于2024年8月12日星期一公布截至2024年6月30日的第二季度财务业绩。交易收盘后，并将于美国东部时间下午 4:30 举行电话会议。
Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
希望参加的人员必须通过以下链接注册参加电话会议： 点击这里注册。注册的参与者将收到一封电子邮件，其中包含电话会议详细信息和拨入选项。为避免延迟，我们鼓励参与者在预定开始时间前 15 分钟拨入电话会议。
A live webcast of the call will also be accessible under the Investors & News section of Lisata's website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
电话会议的网络直播也将在以下网址下观看 投资者与新闻 Lisata网站的部分，将在电话会议结束两小时后开始重播，为期12个月。
About Lisata Therapeutics
关于 Lisata Therapeu
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information on the Company, please visit .
Lisata Therapeutics 是 处于临床阶段的制药公司 致力于发现、开发和商业化治疗晚期实体瘤和其他主要疾病的创新疗法。Lisata的候选产品certepide（前身为 LSTA1）是一种在研药物，旨在激活一种新的摄取途径，该途径允许共同给药或联用抗癌药物更有效地选择性靶向和穿透实体瘤。Lisata已经在其基础上建立了值得注意的商业和研发合作伙伴关系 CendR 平台技术。该公司预计将在未来两年内宣布众多里程碑，并相信其预计资本将为2026年初的运营提供资金，其中包括正在进行和计划中的临床试验的预期数据里程碑。有关该公司的更多信息，请访问 。
Contact:
联系人：
Investors
投资者
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Lisata Therapeutics, In
约翰·门迪托
投资者关系和企业传播副总裁
电话：908-842-0084
电子邮件：jmenditto@lisata.com
Media:
媒体：
ICR Westwicke
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
ICR Westwicke
伊丽莎白·科尔曼
高级助理
电话：203-682-4783
电子邮件：elizabeth.coleman@westwicke.com